Does rivaroxaban prevent death, major cardiovascular events, or major bleeding in patients with atrial fibrillation and a bioprosthetic mitral valve compared to warfarin?
Rivaroxaban is noninferior to warfarin for the composite outcome of death, major cardiovascular events, or major bleeding in patients with atrial fibrillation and a bioprosthetic mitral valve.
In patients with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months. (Funded by PROADI-SUS and Bayer; RIVER ClinicalTrials.gov number, NCT02303795.).
Guimarães et al. (2020) studied this question.